Sarah Jessica Parker Severs Ties With Drug Company Mylan Over EpiPen Price Hike

Sarah Jessica Parker is distancing herself from Mylan, the pharmaceutical giant that has hiked up the price of epinephrine auto-injectors (EpiPens).

Sarah Jessica Parker Slams EpiPen Price Hike

Parker had signed on to a campaign with Mylan to help bring attention to anaphylaxis and the importance of EpiPens. At the time, Parker seemed to be a natural surrogate for the health issue, as her 13-year-old son James with husband Matthew Broderick has life-threatening allergies that require him to have an EpiPen on hand at all times.

It came to light earlier this week that Mylan’s EpiPens have jumped in price from $57 to $608 in less than 10 years. Upon learning of the price hike, Parker took to Instagram to announce that she had cut ties with Mylan.

“I was recently involved in an initiative to raise awareness for anaphylaxis. It’s a cause deeply important to me because of my son’s life threatening peanut allergy. The epinephrine auto-injector (EpiPen) is a vital part of our family’s healthcare, as it is for the many who are at risk,” Parker wrote. “I recently learned that the price of the EpiPen has been systematically raised by Mylan to a point that renders the medication cost-prohibitive for countless people. I’m left disappointed, saddened and deeply concerned by Mylan’s actions. I do not condone this decision and I have ended my relationship with Mylan as a direct result of it.”

Parker added, “I hope they will seriously consider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable for whom it it a life-saving necessity.”

A photo posted by SJP (@sarahjessicaparker) on Aug 25, 2016 at 4:02am PDT

Following the uproar about the price of EpiPens, Mylan has vowed to make them more affordable.